SCHEMBL6403042

SCHEMBL6403042

CC(=O)c1cccc(NS(=O)(=O)CN(CCCc2ccccc2)C(=O)CC(C)CCNC(=O)OCc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CACNA1H O95180 1/20 0.38
CASP1 P29466 1/20 0.37
MMP2 P08253 3/20 0.36
MMP9 P14780 3/20 0.36
MMP3 P08254 2/20 0.36
MMP14 P50281 2/20 0.36
MMP1 P03956 1/20 0.36
MMP7 P09237 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403803 0.90 KMT2A (0.45) HTTMEN1KMT2AALDH1A1LMNA
SCHEMBL6401746 0.89 LMNA (0.42) HTTLMNACHRNB2CHRNB4CHRNA3
SCHEMBL6407167 0.85 CA1 (0.42) KMT2AALDH1A1LMNARAB9ACHRNB2
SCHEMBL6403038 0.79 CACNA1H (0.41) HTTMEN1KMT2AALDH1A1LMNA
SCHEMBL6409458 0.79 NPC1 (0.42) KMT2ALMNARAB9A
SCHEMBL6409447 0.74 ALDH1A1 (0.45) HTTMEN1KMT2AALDH1A1LMNA
SCHEMBL7253042 0.73 PTGES (0.42)
SCHEMBL6408733 0.72 CA1 (0.42) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL6403800 0.72 ALDH1A1 (0.42) HTTMEN1KMT2AALDH1A1LMNA
SCHEMBL6401980 0.68 LMNA (0.45) MEN1KMT2ALMNAMAPTCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 HTT 3074/4885MEN1 4533/4885KMT2A 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.